| Size | Price | |
|---|---|---|
| Other Sizes |
| Animal Protocol |
The study describes field protocols for evaluating the attractiveness of methyl eugenol to *Bactrocera dorsalis*.
For the lure mixture study, traps were placed on metal stakes 1 m above the ground and arranged around the periphery of a field. Traps were emptied and rebaited at weekly intervals. Lure treatments were applied to cotton wicks (3.8 cm long, 1.9 cm diameter) placed inside plastic bucket traps. Each wick contained 8 mL of the lure treatment and 2 mL of 95% technical malathion. [1] For the dispenser comparison study, methyl eugenol dispensers were weathered for 2-16 weeks at the University of Hawaii Experiment Station. At 2-week intervals, dispensers were collected, frozen, and stored until bioassay. For the bioassay, weathered dispensers were placed inside plastic bucket traps, which were then placed in guava trees at eye level and arranged in orchards in a randomized complete block design. Data were collected as the mean number of flies per trap per day. [1] |
|---|---|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
…A study included nine healthy adult male and female volunteers. …The mean fasting level of methyleugenol in serum was 16.2 ± 4.0 pg/g wet weight. Peak plasma concentrations occurred at 15 minutes (mean ± standard deviation, 53.9 ± 7.3 pg/g wet weight), followed by a rapid decline; the elimination half-life was approximately 90 minutes. This peak level is consistent with the range of methyleugenol plasma concentrations in the US population, which were measured simultaneously in non-fasting participants during the Third National Health and Nutrition Examination Survey (NHANES III). Metabolism/Metabolites In rats, the allyl side chain of eugenol methyl ether undergoes oxidation to produce three metabolites, two of which are excreted as glycine conjugates. Other metabolic reactions include benzene ring hydroxylation, ortho-demethylation, and two oxidation reactions; accounting for 63–95% of the initial dose. Most metabolites are present in bile. It is known that the human metabolite of methyl eugenol includes 1-hydroxymethyl eugenol. Biological half-life ...The human elimination half-life is approximately 90 minutes. |
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) > 4,800 mg/m3 Non-human Toxicity Values LD50 Rabbit dermal administration > 2025 mg/kg LD50 Rat oral administration 1179 mg/kg LD50 Mouse intraperitoneal injection 540 mg/kg LD50 Mouse intravenous injection 112 mg/kg LD50 Mouse intraperitoneal injection > 640 mg/kg /table/ |
| References |
|
| Additional Infomation |
According to the National Toxicology Program (NTP), methyleugenol is a potential carcinogen. Methyleugenol is a clear, colorless to pale yellow liquid with a pungent, earthy odor and a bitter, burning taste. (NTP, 1992) o-Methyleugenol is a phenylpropanoid compound whose function is related to eugenol. Methyleugenol has been reported in Magnolia officinalis, Taxus chinensis, and other organisms with relevant data. Methyleugenol is a pale yellow, oily natural liquid with a clove-like aroma and is found in many essential oils. Methyleugenol is used as a flavoring agent, spice, and rodent anesthetic. Methyleugenol is mutagenic in animals, and based on evidence of carcinogenicity in animals, there is reason to expect it to be carcinogenic in humans as well. (NCI05) Methyleugenol is found in Allspice. Methyleugenol is found in many essential oils, such as nutmeg and nutmeg peel, and in many fruits, such as apples, bananas, orange juice or peel, grapefruit, and blueberries. Methyleugenol has been shown to have analgesic effects (A7914). Methyleugenol belongs to the anisole class of compounds. Anisole compounds are organic compounds containing methoxybenzene or its derivatives.
Therapeutic Uses Anesthetics Drugs (Veterinary): Methyleugenol, suspended in Tween-80 or polyoxyethylene ether, can be safely administered intraperitoneally at doses of 200 to 275 mg/kg to rats and mice undergoing brain surgery without some of the inconveniences of sodium pentobarbital. |
| Molecular Formula |
C11H14O2
|
|---|---|
| Molecular Weight |
178.23
|
| Exact Mass |
178.099
|
| CAS # |
93-15-2
|
| Related CAS # |
Methyl Eugenol-13C,d3
|
| PubChem CID |
7127
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
254.7±0.0 °C at 760 mmHg
|
| Melting Point |
−4 °C(lit.)
|
| Flash Point |
87.1±22.7 °C
|
| Vapour Pressure |
0.0±0.5 mmHg at 25°C
|
| Index of Refraction |
1.500
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
13
|
| Complexity |
156
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C)C1C(OC)=CC(CC=C)=CC=1
|
| InChi Key |
ZYEMGPIYFIJGTP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H14O2/c1-4-5-9-6-7-10(12-2)11(8-9)13-3/h4,6-8H,1,5H2,2-3H3
|
| Chemical Name |
1,2-dimethoxy-4-prop-2-enylbenzene
|
| Synonyms |
Methyl eugenol Eugenol methyl etherMethyleugenol O-Methyleugenol 3,4-Dimethoxyallylbenzene4-Allylveratrole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~561.07 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.6107 mL | 28.0536 mL | 56.1073 mL | |
| 5 mM | 1.1221 mL | 5.6107 mL | 11.2215 mL | |
| 10 mM | 0.5611 mL | 2.8054 mL | 5.6107 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
